## Program

**13th International Wolfsberg Meeting on Molecular Radiation Biology / Oncology 2013**

**Saturday, June 22, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Details</th>
</tr>
</thead>
</table>
| 14:30-14:40 | Welcoming and Opening Remarks  
H. Peter Rodemann, Tübingen |
| 14:40-16:00 | Young Investigators Platform  
Chair: H. Peter Rodemann, Tübingen |
| 14:40-15:10 | Invited Lecture  
Deric Wheeler, Madison, USA  
*Targeting nuclear EGFR: Strategies for improving cetuximab therapy in cancer* |
| 15:10-15:30 | Late-Breaking Paper  
Saskia Rademakers, Nijmegen, NL  
*Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial* |
| 15:30-16:00 | VARIAN-Juliana Denekamp Award Ceremony |
| 15:30-15:40 | Laudatio |
| 15:40-16:00 | VARIAN-Juliana Denekamp Award Lecture  
Kasper Rouschop, Maastricht, NL  
*PERK-signaling and autophagy activation is required for survival of therapy resistant hypoxic cells* |
| 16:00-19:00 | Topic I: Signaling Cascades and Survival Mechanisms  
Chair: Randi Syljuasen, Oslo / Nils Cordes, Dresden |
| 16:00-18:00 | Poster Session |
| 18:00-19:00 | Proffered Papers |
| 18:00-18:20 | Bo Xu, Birmingham, USA  
*Hyperactive DNA damage response promotes breast cancer metastasis* |
| 18:20-18:40 | Malin Lando, Oslo, NO  
*Genetic loss and hypermethylation of 3p genes as biomarkers of chemoradioresistance in cervical cancer* |
| 18:40-19:00 | Barry Jütten, Maastricht, NL  
*Inhibition of autophagy abrogates the survival advantages of EGFRvIII+ cells under metabolic stress and sensitizes tumors to irradiation* |
| 19:30 | Wolfsberg Barbecue |
Topic II: DNA Damage Response: Basic Mechanisms and Clinical Perspectives
Chair: Conchita Vens, Amsterdam / Ekkehard Dikomey, Hamburg

08:00-08:30 Invited Lecture
Bernard Salles, Toulouse, FR
A new way to follow the production of DNA double-strand breaks in cells in real time

08:30-09:00 Invited Lecture
Anthony Chalmers, Glasgow, UK
Tumor-specific radiosensitization by inhibition of PARP

09:00-11:00 Poster Session

11:00-12:00 Proffered Papers

11:00-11:20 Sandeep Burma, Dallas, USA
Phosphorylation of Exo1 by CDK1 and CDK2 regulates the choice between NHEJ and HR DNA repair pathways

11:20-11:40 Nathan T. Martin, Los Angeles, USA
ATM-dependent MiR-335 targets CtIP and modulates the DNA damage response

11:40-12:00 Kum Kum Khanna, Brisbane, AUS
Essential developmental, genomic stability and tumour suppressor functions of the mouse orthologue of hSSB1/NABP2

12:00-13:30 Lunch
**Sunday, June 23, 2013**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00-18:00</td>
<td><strong>Topic III: Biomarkers and Targeting Strategies: Basic Mechanisms and Clinical Perspectives</strong>&lt;br&gt;Chair: Stephan Bodis, Aarau / Jens Overgaard, Aarhus</td>
</tr>
<tr>
<td>14.00-14:30</td>
<td><strong>Invited Lecture</strong>&lt;br&gt;Anna Dubrovska, Dresden, GER&lt;br&gt;<strong>Cancer stem cells: A source of radioresistance and therapeutic target</strong></td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Invited Lecture</strong>&lt;br&gt;Michael Baumann, Dresden, GER&lt;br&gt;<strong>Clinical perspectives of cancer stem cell research in radiation oncology</strong></td>
</tr>
<tr>
<td>15:00-17:00</td>
<td><strong>Poster Session</strong></td>
</tr>
<tr>
<td>17:00-18:00</td>
<td><strong>Proffered Papers</strong></td>
</tr>
<tr>
<td>17:00-17:20</td>
<td>Philippe Lambin, Maastricht, NL&lt;br&gt;<strong>Mitochondrial DNA variation is a valuable biomarker for the development of radiation-induced lung toxicity</strong></td>
</tr>
<tr>
<td>17:20-17:40</td>
<td>Paul M. Harari, Madison, USA&lt;br&gt;<strong>Combining radiation with next generation EGFR targeting agents: MEHD7945A and SYM004</strong></td>
</tr>
<tr>
<td>17:40-18:00</td>
<td>C. Nicolaj Andreassen, Aarhus, DK&lt;br&gt;<strong>Independent prospective validation of a predictive test for risk of radiation induced fibrosis based on the gene expression pattern in fibroblasts irradiated in vitro</strong></td>
</tr>
<tr>
<td>18:45-20:00</td>
<td><strong>Wolfsberg Cup (sports event)</strong></td>
</tr>
<tr>
<td>20:15</td>
<td><strong>Wolfsberg Dinner</strong></td>
</tr>
</tbody>
</table>
Monday, June 24, 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 08:00-12:00| **Topic IV: Tumor and Normal Tissue Microenvironment: Basic Mechanisms and Clinical Perspectives**  
Chair: Albert van der Kogel, Nijmegen / Bradly Wouters, Toronto |
| 08:00-08:30| **Invited Lecture**  
Thomas Iftner, Tübingen, GER  
*Role of HPV in cancer development* |
| 08:30-09:00| **Invited Lecture**  
Jesper Eriksen, Odense, DK  
*Challenges in the treatment of HPV-positive head and neck squamous cell carcinomas* |
| 09:00-11:00| **Poster Session** |
| 11:00-12:00| **Proffered Papers** |
| 11:00-11:20| Thorsten Rieckmann, Hamburg, GER  
*HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to impaired DSB repair capacity* |
| 11:20-11:40| Richard P. Hill, Toronto, CA  
*Hypoxia and metastasis in an orthotopic cervix cancer xenograft model* |
| 11:40-12:00| Marianne Koritzinsky, Toronto, CA  
*Reprogramming metabolism with metformin improves tumor oxygenation and radiation response* |
| 12:00-12:15| **Presentation of the Wolfsberg Poster Awards and Closing Remarks** |
| 12:15-13:15| *Lunch* |
| 13:30    | **Bus departure to Zürich Airport** |
Posters presented during the topic-specific Poster Sessions

**Posters Topic I  Signaling Cascades and Survival Mechanisms**

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Presenting author and title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI.1</td>
<td>Shafiq U Ahmed, Glasgow, UK: Glioma stem cell radioresistance is associated with preferential activation of the G2/M cell cycle checkpoint</td>
</tr>
<tr>
<td>PI.2</td>
<td>Gabriele Niedermann, Freiburg, GER: Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells</td>
</tr>
<tr>
<td>PI.3</td>
<td>Justine Rudner, Essen, GER: The deubiquitinase USP9x confers resistance to apoptosis induced by ionizing radiation through stabilizing anti-apoptotic Mcl-1</td>
</tr>
<tr>
<td>PI.4</td>
<td>Eva Bozsaky, Vienna, A: The role of apoptosis in the oral mucositis – experimental studies</td>
</tr>
<tr>
<td>PI.5</td>
<td>Malte Kriegs, Hamburg, GER: New strategies in HNSCC treatment: Sorafenib sensitizes HNSCC cell lines, resistant towards anti-EGFR therapy</td>
</tr>
<tr>
<td>PI.6</td>
<td>Hanneke Stegeman, Nijmegen, NL: Dasatinib inhibits DNA repair specifically in pSFK expressing tumor areas in head and neck xenograft tumors</td>
</tr>
<tr>
<td>PI.7</td>
<td>Marina Bechtel, Tübingen, GER: Role of PI3K/Akt signaling in the differential radiation response of NSCLC cells to rapamycin in vitro</td>
</tr>
<tr>
<td>PI.8</td>
<td>Mahmoud Toulany, Tübingen, GER: Inhibition of ATM kinase improves cisplatin-induced radiosensitization of NSCLC cells</td>
</tr>
<tr>
<td>PI.9</td>
<td>Valentine M. Macaulay, Oxford, UK: IGF-1R inhibition influences repair of temozolomide (TMZ)-induced double strand breaks (DSBs) and sensitizes human melanomas to TMZ</td>
</tr>
<tr>
<td>PI.10</td>
<td>Kunal Lodhia, Oxford, UK: Suppression of homologous recombination (HR) increases sensitivity to type 1 IGF-receptor (IGF-1R) inhibition</td>
</tr>
<tr>
<td>PI.11</td>
<td>Peter Sminia, Amsterdam, NL: PI3K-Akt pathway inhibition and irradiation in human malignant glioma cells</td>
</tr>
<tr>
<td>PI.12</td>
<td>Melanie Spitzner, Göttingen, GER: Targeting STAT3 in vitro and in vivo reveals a novel therapeutic strategy to sensitize colorectal cancer cells to chemoradiotherapy</td>
</tr>
<tr>
<td>PI.13</td>
<td>Toni M. Brand, Madison, USA: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer</td>
</tr>
<tr>
<td>PI.14</td>
<td>Claudia Fournier, Darmstadt, GER: Inflammation related interaction between primary human endothelial cells and lymphocytes is modified after radiation exposure under shear stress</td>
</tr>
<tr>
<td>PI.15</td>
<td>Marion Scharplenecker, Amsterdam, NL: Endoglin regulates function and normal tissue damage development in the irradiated mouse kidney</td>
</tr>
<tr>
<td>PI.16</td>
<td>Chrysi Petraki, Frankfurt, GER: Survivin XIAP binding site is essential for radiation survival of colorectal cancer cells</td>
</tr>
<tr>
<td>PI.17</td>
<td>Chann Lagadec, Villeneuve d'Ascq, FR: Radiation-induced reprogramming of breast cancer cells</td>
</tr>
</tbody>
</table>

**Posters Topic II  DNA Damage Response / Basic Mechanisms and Clinical Perspectives**

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Presenting author and title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PII.1</td>
<td>Carlos D. Martins, Oxford, UK: Real time studies of DNA repair kinetics following low LET short-pulse MeV electron radiation</td>
</tr>
<tr>
<td>PII.2</td>
<td>Ross Carruthers, Glasgow, UK: Abrogating cancer stem cell radioresistance in glioblastoma via ATM inhibition</td>
</tr>
<tr>
<td>PII.3</td>
<td>Anne E. Kiltie, Oxford, UK: HDAC inhibition as a mechanism of radiosensitisation through DNA damage signalling and repair in bladder cancer</td>
</tr>
<tr>
<td>PII.4</td>
<td>Sabrina Köcher, Hamburg, GER: DNA double-strand break repair by homologous recombination requires ATM but not Artemis during the S-phase</td>
</tr>
</tbody>
</table>
**Posters Topic III  Biomarkers and Targeting Strategies: Basic Mechanisms and Clinical Perspectives**

<table>
<thead>
<tr>
<th>Poster No.</th>
<th>Presenting author and title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PII.1</td>
<td>Jochen Gaedcke, Göttingen, GER: Identification of a microRNA expression signature for radiochemosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let-7g</td>
</tr>
<tr>
<td>PII.2</td>
<td>Mohammad Saki, Berlin, GER: Acquired resistance to cetuximab is associated with overexpression of Ras family members and loss of radiosensitization in head and neck cancer cells</td>
</tr>
<tr>
<td>PII.3</td>
<td>Antje Güttler, Halle, GER: KDM1A histone demethylase expression interferes with stress response and DNA repair in a p53-dependent manner in human neuroblastoma cells</td>
</tr>
<tr>
<td>PII.4</td>
<td>Conchita Vens, Amsterdam, NL: Exploitable DNA repair defects in squamous cell carcinomas of the head and neck</td>
</tr>
</tbody>
</table>
PIII.5 Antje Güttler, Halle, GER: Radiosensitization of normoxic and hypoxic U251 malignant glioma cells expressing IDH1 R132H mutant protein

PIII.6 C. Norman Coleman, Bethesda, USA: Radiation survivors: understanding and exploiting the phenotype of cells that survive clinically relevant radiation fractionation

PIII.7 Philippe Lambin, Maastricht, NL: Long-lasting anti-tumor effect of radiotherapy in combination with the targeted immunocytokine L19-IL2: an effect of cytotoxic T cells?

PIII.8 Martina Zimmermann, Zurich, CH: Combined radiochemotherapeutical strategies for microtubule stabilizing agent (MSA)-resistant tumors

PIII.9 Simone Moertl, Munich, GER: Radiation-induced upregulation of miR-525-3p promotes cell survival by fine tuning of ARRB1 and TXN protein levels

PIII.10 Franziska Eckert, Tübingen, GER: Local irradiation to enhance the anti-tumour effect of immunotherapy with the FP-IL12 fusion protein

PIII.11 Stephanie Hehlgans, Frankfurt, GER: The inhibitor of apoptosis proteins survivin and XIAP modulate both radiosensitivity and the motility of colorectal cancer cells

PIII.12 Franz Rödel, Frankfurt, GER: Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells

PIII.13 Mechthild Krause, Dresden, GER: Improved local tumour control after fractionated irradiation and simultaneous PLK inhibition with volasertib (BI 6727)

PIII.14 Johan Bussink, Nijmegen, NL: EGFR-inhibition enhances apoptosis in irradiated human head and neck xenograft tumors independent of effects on DNA repair

PIII.15 Geoff S. Higgins, Oxford, UK: A high-throughput siRNA screen identifies several novel determinants of tumour radiosensitivity

PIII.16 Kerstin Borgmann, Hamburg, GER: Replication-dependent radiosensitization by inhibition of Poly(ADP-ribose) polymerase depends on the RAD51 expression status

PIII.17 Alexander C Whitley, Birmingham, USA: Radiosensitization by Erlotinib and the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in esophageal squamous cell cancer

PIII.18 Leon A. Kunz-Schughart, Dresden, GER: Arginine depletion as a metabolic targeting strategy to sensitize cancer cells to irradiation

PIII.19 Franziska Niehr, Berlin, GER: The PARP inhibitor olaparib (AZD2281) enhances the effect of irradiation in head and neck cancer cells with resistance to cisplatin and cetuximab

PIII.20 Daniela Schilling, Munich, GER: Effects of the Hsp70 inhibitor NZ28 on radiosensitivity and immunogenicity of tumor cells

PIII.21 Simon J. A. van Kuijk, Maastricht, NL: Targeting of carbonic anhydrase IX by nitroimidazole based sulfamide dual drugs enhances the therapeutic effect of tumor irradiation and chemotherapy

PIII.22 Delphine Poncet, Lyon, FR: Telomere profiling: toward glioblastoma personalized medicine

PIII.23 Natasa Anastasov, Neuherberg, GER: Novel 3D-microtissue technology identifies compounds that modify radiation-therapy response

PIII.24 Navita Somaiah, Sutton, UK: Test of association between Ki67 index of early breast cancer and local relapse after adjuvant hypofractionated radiotherapy

PIII.25 Mark T. W. Teo, Leeds, UK: Germline MRE11A variants as predictive markers of radiotherapy outcomes in muscle-invasive bladder cancer

PIII.26 Michael C. Joiner, Detroit, USA: High-throughput qPCR for determining absorbed radiation dose: comparison of mouse and man

PIII.27 Claire von Neubeck, Dresden, GER: GammaH2AX as a clinical relevant biomarker for local tumor control after radiotherapy

PIII.28 Ina Kurth, Dresden, GER: Cancer stem cell related biomarkers of radioresistance in head and neck squamous cell carcinoma

PIII.29 Claudia Peitzsch, Dresden, GER: Prostate cancer stem cells biomarkers as a predictor of response to radiotherapy

PIII.30 Niloy R. Datta, Aarau, CH: Does the quantum of local tumour HPV positivity in cervix cancers lead to a radiobiologically different tumour cell population?

PIII.31 Stephanie E. Combs, Heidelberg, GER: Impact of MGMT, IDH-1, EGFR and PTEN on outcome in patients with glioblastoma treated with ERBITUX® (Cetuximab), radiation and Temozolomide (GERT)

PIII.32 C Herskind, Mannheim, GER: Changes in p53 levels after in vivo and in vitro irradiation of fibroblasts from breast cancer radiotherapy patients with and without late reaction
PIII.33 Ashish Sharma, Zuerich, CH: Secretome profiling for identification of ionizing radiation-activated acquired resistance mechanisms

PIII.34 Alan Dal Pra, Toronto, CA: TMPRSS2-ERG status as a prognostic factor following radiotherapy for intermediate-risk prostate cancer

PIII.35 Christian Ostheimer, Halle, GER: Elevated plasma levels of OPN, CA-IX and VEGF as a prognostic biomarker panel in lung cancer treated with radiotherapy

PIII.36 Jeffrey Bruce, Toronto, CA: The role of microRNAs in human nasopharyngeal carcinoma

PIII.37 Apostolos Menegakis, Tübingen, GER: Experimental evaluation of a novel assay to predict tumour radiation sensitivity

PIII.38 Ann Rita Halvorsen, Oslo, NO: Radiation induced methylation changes in breast cancer impacts the therapy response

PIII.39 Monique C. de Jong, Amsterdam, NL: Micro-messenger-RNA combinations indicate that EMT before irradiation predicts radiosensitivity of head and neck cancer cell lines

PIII.40 Philip Wong, Toronto, CA: A micro-RNA Signature that predicts for distant metastasis in undifferentiated pleomorphic sarcomas

PIII.41 Eva-Maria Thurner, Graz, A: Single nucleotide polymorphisms in the RAD51, BRCA1 and BRCA2 genes and radiation-induced morbidity in prostate cancer patients

PIII.42 Christopher D. Willey, Birmingham, USA: Kinomic modeling of temozolomide and radiation response from patient-derived GBM xenolines

Posters Topic IV Tumor and Normal Tissue Microenvironment: Basic Mechanisms and Clinical Perspectives

Poster No. Presenting author and title

PIV.1 Frank Pajonk, Los Angeles, USA: The RNA-binding protein Musashi-1 regulates proteasome subunit expression in breast cancer and glioma CSCs/tumor-initiating cells

PIV.2 Paul N. Span, Nijmegen, NL: The PERK/ATF4/LAMP3-arm of the unfolded protein response is involved in resistance to radiation by interfering with the DNA damage response

PIV.3 Heidi Lyng, Oslo, NO: Depletion of membranous moesin associates with downregulation of immune genes and chemoradioresistance of lymph node positive cervical cancer

PIV.4 Erina Vlashi, Los Angeles, USA: rhEpo synergizes with radiation in enriching the breast cancer stem cell pool explaining inferior treatment outcomes in the clinic

PIV.5 Natividad Gomez-Roman, Glasgow, UK: Effects of extracellular matrix and two- and three-dimensional growth conditions on radiation responses of glioblastoma stem cells in vitro

PIV.6 Diana Klein, Essen, GER: Radiation-induced normal tissue damage stimulates invasion and metastasis formation of circulating tumor cells

PIV.7 Vincent A. Potiron, Nantes, FR: Vascular remodeling during fractionated radiation therapy in a prostate cancer model

PIV.8 Jan Theys, Maastricht, NL: High NOTCH activity induces radiation resistance in non small cell lung cancer (NSCLC)

PIV.9 Daniela Trani, Maastricht, NL: Preclinical assessment of Fluorodeoxyglucose (FDG) uptake-based radiation dose painting for the treatment of solid tumors

PIV.10 Katja Storch, Dresden, GER: Should we stay or should we go? Does X-ray or carbon ion irradiation impair glioblastoma 2D cell migration and 3D invasion in vitro?

PIV.11 Julien Verrax, Brussels, B: Inhibition of a metabolic symbiosis based on lactate exchange between tumor cells induces a glycolytic switch sensitizing tumors to radiotherapy

PIV.12 Monica M. Olcina, Oxford, UK: Specific epigenetic changes are required for the activation of ATM in response to hypoxia

PIV.13 Hassan Chaachouay, Tübingen, GER: Hypoxia induced autophagy: an adaptive strategy promoting radioresistance of tumor cells in vitro

PIV.14 Harald Bull Ragnar, Oslo, NO: Micrometastases and pimonidazole staining in a surgical cohort of prostate cancer
Marco Schaaf, Maastricht, NL: ULK1 promotes hypoxia-induced autophagy

Tom G. Keulers, Maastricht, NL: Targeting GABARAPL1, a hypoxia induced protein, after irradiation inhibits tumor regrowth

Cindy Korner, Oxford, UK: Hypoxia-activated Chk1 inhibition sensitizes cells to hypoxia/reoxygenation

Martin-Immanuel Bittner, Freiburg, GER: Tumour hypoxia in locally advanced head-and-neck tumours during primary chemoradiotherapy in serial 18-F-MISO-PET imaging

Cathinka Halle, Oslo, NO: Epigenetic changes associated with hypoxia-related chemoradioresistance in cervical cancer

Twan van den Beucken, Maastricht, NL: Hypoxia promotes metastatic and tumour stem cell phenotypes through inhibition of DICER and miRNA biogenesis

Lydia Koi, Dresden, GER: Microenvironmental parameters and local tumour control after radiochemotherapy combined with nimorazole

Dan Cojocari, Toronto, CA: New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1 is essential for promoting adaptation and survival to hypoxia

Jan Alsner, Aarhus, DK: Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells

Grete Hasvold, Oslo, NO: G2 checkpoint signaling in hypoxic cells

Arnulf Mayer, Mainz, GER: Multiparametric immunohistochemistry in registered serial sections (MIRSS): A novel method for the characterization of the tumor microenvironment

Natalie Burrows, Manchester, UK: Radiotherapy enhances metastatic characteristics of thyroid carcinoma via a PI3K/Rac1/Cdc42/Rho and HIF-1 dependent and FAK/SRC independent mechanism

Ellen Dickreuter, Dresden, GER: Targeting of beta1 integrin results in radiosensitization and affects NHEJ DNA repair in HNSCC cell lines

Adriana Haimovitz-Friedman, New York, USA: Targeting vascular endothelium for radiosensitization and tumor cure

Annelies Debucquoy, Leuven, B: Combining bevacizumab and chemoradiation in rectal cancer: encouraging clinical and translational results of the AXEBeam trial

Rob P. Coppes, Groningen, NL: Salivary gland CD24hi/CD29hi stem cells self-renew, differentiate in vitro and rescue radiation-induced hyposalivation

Laura K. van Dijk, Nijmegen, NL: 111In-cetuximab-F(ab')2 SPECT imaging to assess treatment response in HNSCC xenografts

David F. Antoran, Cambridge, UK: Lineage tracing reveals dynamics of esophageal progenitor cells in homeostasis, injury and during treatment with tyrosine kinase inhibitors
The organizers would like to gratefully acknowledge the financial support of the 13th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2013 by the institutions and scientific organizations listed below. Without their donations the meeting would not have been possible.

**Deutsche Gesellschaft für Radioonkologie (DEGRO), GER**

**European Society for Therapeutic Radiology and Oncology (ESTRO), B**

Krebbsliga Schweiz, CH

Lieselotte Beutel Stiftung, GER

Medipan GmbH, GER

Merck Serono S. A., CH

Merck KGaA, GER

**Österreichische Gesellschaft für Radioonkologie (ÖGRO), A**

Philips AG, Healthcare, CH

Roche Pharma (Schweiz) AG, CH

**SASRO, CH**

Schweizerischer Nationalfonds (SNF), CH

Universitätsklinikum Tübingen, GER

Universitätsspital Zürich, CH

Varian Medical Systems Int. AG, CH

**Xstrahl Ltd., UK**